ARON 3D_Transparent

Urothelial Carcinoma

Geo diff

Geographical Differences in the Management and Outcomes of PatientsWith Advanced Urothelial Carcinoma Treated With Pembrolizumab AfterProgression on Platinum-Based Chemotherapy: Results From ARON-2Study

Rizzo M,
JCO Glob Oncol.
2025
Concomitant Med ARON 2

Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study

Fiala O
et al. Clin Exp Metastasis
2025
Sequences ARON 2

Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Rizzo M
et al. Cancer Med
2025
Sex ARON 2

Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab

Incorvaia L,
et al. Sci Rep.
2025
1n0qB6 VSRGWzc098ji9sg

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 

Massari F, et al.
Cancer Immunol Immunother.
2024
1733809351923

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.

Santoni M, et al.
Cancer Immunol Immunother.
2023

Do you want to join us ?

Join us today
ARON 3D_Transparent
Youtube Linkedin

Coordinated and designed by Atteggiamento Digitale .

Legal and Privacy.